47 results about "Prevotella" patented technology

The present invention relates to a vaccine for the prevention of lactic acidosis in a vertebrate, said vaccine comprising at least one isolated microorganism, or fragment or fragments thereof, wherein said microorganism is capable of producing lactic acid within the gut of said vertebrate, and wherein said microorganism is selected from the group consisting of: Clostridium-like species, Prevotella-like species, Bacteroides-like species, Enterococcus-like species, Selenomonas species, non-dextran slime producing Streptococcus species and non-slime producing lactic acid bacterial isolates.

The invention discloses a mental disorder related intestinal tract microbial marker and application thereof. The intestinal tract microbial marker refers to one or more combinations of intestinal tract microbial florae of Prevotella and Bacteroides. The invention further discloses application of the mental disorder related intestinal tract microbial marker in preparing reagents for diagnosing mental disorders and methods for screening food, probiotics or drugs capable of intervening with mental disorders. Particularly, the methods include comparing proportion of microbial florae of Prevotella to microbial florae of Bacteroides before and after treatment or interference of the food, probiotics or drugs and/or comparing relative quantity of microbial florae of Prevotella and microbial florae of Bacteroides in feces specimens.

The invention discloses an application of an enteric microorganism as a marker of bronchial pulmonary dysplasia of a premature infant. The enteric microorganism is one or more of Klebsiella, Prevotella and Streptococcus. The application comprises the following steps: sequencing a separated intestinal flora nucleic acid sample to obtain a sequencing result, detecting the relative abundance of the intestinal microorganisms in the intestinal flora according to the sequencing result to obtain a relative abundance value, and comparing the obtained relative abundance value of the intestinal microorganisms with a set value, and taking the obtained result as intermediate information to assist in diagnosing the premature bronchial pulmonary dysplasia. The premature infant excrement sample 16SrDNA gene is sequenced through a high-throughput sequencing technology, the relationship between intestinal flora and premature infant BPD occurrence is discussed for the first time, and a reliable basis is provided for prevention and treatment of BPD.

The invention discloses establishment of an intestinal tract micro-ecological map of a longevity family and an application of the intestinal tract micro-ecological map in the field of aging health. Itis discovered that the following microorganisms including at least one of bacteroides-prevotella, porphyromonadaceae, parabacillus, anaerobic cocci and bifidobacterium adolescentis can be used to more comprehensively observe the flora distribution of the intestinal tracts of longevity crowds, a new marker is provided for diagnosing the health condition of the body and predicting the life of the human body, and more reasonable diet and nutrition suggestions are provided for the healthy life of people. Meanwhile, a new method and thought are provided for research on a mechanism of interaction between metabolites of intestinal microorganisms of the longevity crowds and the bodies, an anti-aging treatment mechanism is clearer, and a solid theoretical basis is provided for research on novel conditioning products including microecological preparations, viable bacterial drugs, fecal microbiota transplantation, nutrient products and the like.

The invention relates to the biomedical field and the field of gene recombination, more specifically, to a preparation method of a recombinant Prevotella asparaginase, which includes the steps of amplifying full length or fragment DNA of asparaginase from the genomic DNA of Prevotella using PCR technique, performing ligation of the obtained DNA and a cloning plasmid with ligase, cutting out the full length or fragment DNA of the asparaginase from the cloning plasmid and then inserting into an eukaryotic expression vector, transforming into Escherichia coli, culturing transformed Escherichia coli in a selective medium containing antibiotic to amplify the expression vector containing the full length or fragment DNA of asparaginase, collecting transformed bacteria, and centrifugating to separate the bacteria; disrupting the bacteria, and releasing the recombinant asparaginase; and performing two-step column chromatography to purify the recombinant Prevotella asparaginase. The inventive method has the advantages of few process steps, controllable quality and large production quantity.

A method for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and may also be encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced. In other embodiments, a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii is administered, or a composition comprising modified L. reuteri bacteria having the ability to survive conditions in the duodenum or jejunum of the individual's small intestine. Other embodiments include the administration of a bacterial formulation comprising at least one of Coprococcus, Veillonella, Roseburia, Bifidobacterium, Faecalibacterium prausnitzii and Prevotella.

The invention discloses application of prevotella in preparation of a medicine for treating cholestatic diseases. The cholestatic diseases include, but is not limited to, primary sclerosing cholangitis. After the inventor constructs a PSC animal model, it is determined that the abundance of P.copri in mice is consistently reduced in the same population, then intervention effects of P.copri on inflammation, fibrosis, cholestasis and the like of the PSC model are observed and evaluated through intragastric administration for one week and daily supplementation of 1*10<8> CFU of P.copri bacterial liquid, bile acid metabolism changes are determined through total bile acid determination and targeted bile acid detection analysis, and the action mechanism is analyzed. Experiments prove that the P.copri can obviously relieve cholestasis in hepatointestinal circulation of PSC mice and obviously improve liver fibrosis, which is of great significance to prevention or treatment of cholestatic diseases.

The invention provides an application of speckled prevotella in treatment or prevention of rheumatoid arthritis or related diseases thereof, and also provides speckled prevotella containing pharmaceutical compositions, medicaments, foods and feeds. By providing speckled prevotella for animals, an anti-inflammatory effect can be effectively played, the symptoms such as redness and swelling of joints are effectively improved, the symptoms of arthritis are obviously relieved, and therefore, the speckled prevotella can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.

The invention provides intestinal flora microorganisms for evaluating sexual precocity of children. The method comprises the following steps of: comparing intestinal flora data of an object with intestinal flora data of healthy children; and mainly analyzing the relative abundance of streptococcus, neisseria, haemophilus, porphyromonsginglivlis, megacoccus, phascolarctobacterium, clostridium, coprococcus and prevotella, wherein the relative abundance of the streptococcus, the neisseria, the haemophilus and the porphyromonsginglivlis is reduced, and the relative abundance of the megacoccus, thephascolarctobacterium and the clostridium is increased. Therefore, the streptococcus, the neisseria, the haemophilus, the porphyromonsginglivlis, the megacoccus, the phascolarctobacterium and the clostridium have higher specificity and sensitivity. Therefore, the streptococcus, the neisseria, the haemophilus, the porphyromonsginglivlis, the megacoccus, the phascolarctobacteriumand the clostridiumhave higher specificity and sensitivity. In the process of evaluating the sexual precocity of children, detection and research results are compared to evaluate the level change of intestinal flora microorganisms of children, and whether the risk of the sexual precocity exists or not is judged according to the level change of the intestinal flora microorganisms.

The problem is solved by an upper gastrointestinal flora-improving agent, the agent containing lactic acid bacteria as an effective ingredient, to be used in persons positive and negative for Helicobacter pylori. Lactic acid bacteria of the genus Lactobacillus is preferably used as the lactic acid bacteria, more preferably Lactobacillus gasseri OLL2716 (FERM BP-6999). Improvement of the upper gastrointestinal flora is, for example, a reduction in upper gastrointestinal Bifidobacterium and/or an increase in upper gastrointestinal Prevotella.

A method for determining the risk of an adverse pregnancy outcome for a woman is provided comprising the steps of measuring a level of TM7-H1 and optionally one or more of BVAB1, Sneathia amnii, and Prevotella cluster 2 in a vaginal sample obtained from the woman, and identifying the woman as having an increased risk for an adverse pregnancy outcome, or other adverse pregnancy outcomes, if the levels are increased compared to corresponding standard control levels. Methods for the prophylactic treatment of subjects identified as being at increased risk for an adverse pregnancy outcome are also provided.

The invention discloses a stable coronary heart disease onset risk assessment marker and application thereof. The markers comprise bacteroides martensii, unclassified Eagle's bacilli, klebsiella pneumoniae, unclassified clostridium, unclassified pararevovirus, helicobacter sp. 5163FAA, anaerobic corynebacterium faecalis, unclassified biliphilic bacteria, human rosiberia, Eubacterium abdominalis, human body prevotella, pasteurella gut, wood anise bacilli, Eubacterium and unclassified megamonas. , bacillus pleurati, parabacterium and escherichia coli. According to the method, the onset risk of the stable coronary heart disease is predicted, and the prediction accuracy can be improved.

A system and method for reducing the likelihood of colorectal cancer in a human being includes the modification of an individual's gut microbes by employing a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system to modify only bacterial genes of bacteria that reside in the human gut that are non-homologous to those encompassed in the human genome, and in particular, to administer a therapeutically effective amount of a bacterial formulation comprising F. prausnitzii that has been modified to produce one of alliin or butyrate.